Aetna: Entresto’s Label Enabled Outcome-Based Risk Share
Executive Summary
Including the impact on hospitalizations in the label for Novartis's heart failure drug Entresto was critical to enable execution of outcome-based agreements. Such deals present an opportunity for pharma and payers to work together, but many challenges remain.
You may also be interested in...
Novartis Woos Payers With Data Showing Entresto Earns Its Keep
With Entresto sales slowly climbing to $53m in third quarter, Novartis releases data supporting value of heart failure drug in preventing costly hospitalizations at the annual American Heart Association meeting.
Smart Segmentation: Success In The Payer-Dominated Pharma Marketplace
As physicians lose decision-making authority to payers, argues Roger Longman of Real Endpoints, drug companies need to segment markets more effectively: the patient populations prescribers are most likely to treat and that will spark the fewest access battles; and the specific payer lines-of-business least inclined to block new drugs' use.
Does Novartis Need A Big Immuno-Oncology Deal? Jimenez Says No
The oncology player missed out on the first round of immune checkpoint inhibition and now some investors are wondering if the pharma needs to buy a rival to catch up. During the company’s second quarter sales call CEO Jimenez insisted Novartis has the internal expertise to execute.